### Definition of the immunological properties of cancer stem cells isolated from human glioblastoma


Cristina Maccalli

Unit of Immuno-biotherapy of Melanoma and Solid Tumors Division of Molecular Oncology San Raffaele Scientific Institute, Milan, Italy


> iSBTc 24th Annual meeting Washington DC, 30/10/2009



SAN RAFFAELE



#### Neurospheres and the neurosphere assay




Das 8 et al. (2008) Canoor stem cells and pliome Net Can Pract Network 10,1038/hopme.iro0802

#### CSCs can be defined as:

#### 1) self-renewing cells;

- 2) cells that give rise to the variety of differentiated cells found in the malignancies (multipotency);
- 3) cells able to generate a phenocopy of the orignal malignancy in immunocompromised mice (tumorigenic ability).

#### Self renewal, tumorigenicity and differentiation ability of GBM CSCs



#### EXPRESSION OF NEURAL STEM CELL-ASSOCIATED MOLECULES AND OF TRANSCRIPTION FACTORS BY GBM CSCs AND FBS TUMOR CELLS.

Cell Line	Molecule								
	с-Мус	Nestin	Nanog	S100A4	S100A6	Sall4	SOX2		
080125 CSCs	2	n.d.	2	2	2	5	7		
080125 FBS	2	n.d.	4	2	2	8	3		
080418 CSCs	2	35	2	2	4	4	38		
080418 FBS	4	15	2	1	2	3	20		
080325 CSCs	1	n.d.	3	4	2	3	15		
080325 FBS	1	n.d.	4	1	1	n.d.	8		


Data are represented as MRFI that is the ratio between the mean of intensity of fluorescence of the cells stained with the selected mAb and that of the negative control; bold value means MRFI  $\geq$  2.

#### Expression of MHC and APM molecules and NKG2DLs in GBM-derived CSCs and FBS tumor cells


- <u>The expression of:</u>
- □ MHC class I and II;
- **Antigen processing machinery (APM)**, using 21 different mAbs directed against HLA molecules, their heavy chains, β2-microglobulin immunoproteasome, constitutive proteasome subunits, chaperon molecules, TAPs etc.;


#### **□ NKG2DLs;**

☐ has been tested in 11 different GBM CSCs and, for 5 of them, in their paired tumor cells grown in the presence of FBS (FBS tumor cells).




#### APM expression and modulation in CSCs vs FBS tumor cells






#### **TAA expression in GBM CSCs**

#### Survivin, COA-1 AND SOX2 WERE COMMONLY EXPRESSED IN BOTH CSCs AND FBS TUMOR CELLS; NO EXPRESSION OF MAGE, NY-ESO-1, GP100 AND IL-13Rα2 WAS FOUND.



080125

071210



#### CSCs can elicit autologous t cell-mediated immune responses

B	T cells	CD4/CD8	Target Cells							
	1.0.1.0.1.1.1		Ly alone	070104 CSCs	+ W6/32	+ 1.243	0627 CSCs HLA mismatched	OKT3		
	2	5/95*	16	20	9	17	7	56		
	3	9674	1	2	1	1	1	8		
	10	20 / 76	2	13	N.D.	N.D.	1	24		


\*Results represent the percentage of CD4 and CD8 positive T cells.
\*Results represent the percentage of CD107a positive T cells.


#### Reactivity against CSC or FBS tumor cell lines in autologous setting by T lymphocytes isolated from 4 GBM patients

Patient	T cell line	Autologous	Autologous	MHC-	Cytokine	ТН
#	#	CSC	FBS tumor	restriction	release	type
		recognition	cell	а		subset
	1		recognition	1		
070104	2	++++ b	N. A.	MHC I	IIN	TH1
070104		+++			IFN-γ	
	3	+++	N.A.	MHC II	IFN-γ	TH1
1	10	+++	N. A.	МНСІ	IFN-γ	TH1
080325	1	+	+++	MHC II	IL-5	TH2
	2	+	++	MHC1	IFN-γ	THI
	4	+	++	MHC II	IL-5	TH2
080125	4	+	++	мнс и	115	тн2
080418	1	+	+	-	IL-5	TH2

+:  $\text{\AAB}0 < 100 \text{ spots}/4x10^4 \text{ T cells}$ ; ++:  $\text{\AAB}00 < 200 \text{ spots}/4x10^4 \text{ T cells}$ ; +++:  $\text{\AAB}00 < 800 \text{ spots}/4x10^4 \text{ T cells}$ ;

N.A.: FBS tumor cells are not available;






PBMc were stimulated in vitro with mitogens with or without GBM CScs or FBS tumor cells; after 72 and 120 hrs the proliferative ability of of CD3+ gated cells was analyzed by CFSE staining and cytofluorimetric analysis.

this experiment has been repeated twice.

The proliferative index and the divison index were also calculated.


#### Whole transcriptome analysis of CSCs vs. FBS tumor cells



**GFD vs FBS comparison:** Fold>1.5, p<0.005, permutation p<0.017 469 genes, 393 gene pass 80% present filter.

See gene data list analysis output file and attached


#### Genes involved in canonical pathways



#### Immune related Gene profile signature

- **C** Genes with immunological function were differentially expressed in CSCs vs FBS tumor cells.
- □ In particular the proteosome maturation protein and the proteasome activator subunit 1 were down-modulated (-1,8 and -2.4 fold change, respectively) in CSCs compared to FBS tumor cells correlating with alterations we found at protein level of APM molecule (i.e. MB1) expression.
- Genes related to IFN signaling, such as IFN regulatory factor binding 2 protein (2.7 fold), Tax1 (3,2 fold), IFNGR1(1,7 fold) and the TNF receptor-associated factor 2 (TRAF2) (1,8 fold) were also under expressed in CSCs in comparison with FBS tumor cells.
- ✓ Notably, IL-6 and IL-8 were also found down-modulated in CSCs vs FBS tumor cells and these findings correlating with protein secretion levels we have detected in the supernatants of these cell lines
- $\Gamma$  No differential gene expression of IFN-α, IFN-β, TNFR and IL-1 was detected between CSCs and FBS tumor cells.
- Conversely, genes involved in JAK-STAT signal pathway were found up-regulated (2 fold) in CSCs compared to FBS tumor cells, in line with the previously reported evidence that members of this protein family were aberrantly activated in a variety of tumors including GBM (Bromberg, 2002; Brantley et a., 2008).

## Secretion of suppressive or pro-inflammatory cytokines by CSCs vs. FBS tumor cells



CYTOKINE DETECTION IN THE SUPERNATANTS WAS DETECTED BY ELISA OR SEARCHLIght ASSAYS; NO DETECTION IN THE SUPS OF IL-10, IL-13 AND TNF-A WAS OBSERVED.

#### Immunobiological differences between CSC and FBS tumor cell lines.

-	Immune-related molecules/activity							
	MHC I	МНС	NKG2DLs	APM	IFN	5-Aza-	T cell-	Supressive
		п			modulation	(CdR) <sup>b</sup>	mediated	activity
					а		recognitio	
							n	
CSCs	+	-/+	+/-	+	+	+/-	+	++
FBS	++	-/+	+/-	++	++	++	++	+/-
-			Stem cel	l-associa	ted molecule a	nd/or TA	A	
	Nestin	S100A	S100A6	SOX2	Survivin	COA-1	GP100	NY-ESO-1
		4						
CSCs	+++	++	++	+++	+++	+++	-	-
FBS	+	+	+	++	+++	+++	-	-

a: modulation of the expression of MHC, NKG2D and APM molecules following *in vitro* treatment of the cells with either IFN- $\alpha$  or- $\gamma$ ;

b: modulation of the expression of MHC, NKG2D and APM molecules following *in vitro* treatment of the cells with the demethylating agent 5-Aza.-(CdR).

**CSCs** 

### Conclusions

- A Low immunogenic profile was found in both CSCs and FBS tumor cells isolated from GBM patients, with higher defective APC pattern in CSCs;
- the immune profile can be rescued, though more efficiently in FBS tumor cells, by treatment with IFNs or with 5-Aza-CdR of GBM cell lines;
- ☐ T cell-mediated immune responses can be isolated from GBM patients, though mostly TH2mediated subset;
- Differential gene signature, including immune related genes, was detected in CSCs vs FBS tumor cells; in some cases we could confirm these results at the protein levels (ELISA; SEarchLight).

#### **Future directions**

- **To identify the TAA recognized by anti-GBM CSC T lymphocytes;**
- **To carry out functional experiments based on gene profile data to possibly identify CSC-associated markers and/or TAA;**
- □ to investigate whether the ability of CSCs to elicit T cell-mediated immune responses can be increased by usage of antagonist mAbs directed against negative immune regulatory molecules (anti-CTLA-4 or -PD-L1);
- ☐ to translate all the obtained information to design CSC-specific immunotherapy protocols for GBM patients.

### ACKNOWLEDGEMENT

Unit of Immunotherapy of Melanoma and Solid ۲ Tumors, Div. Molecular Oncology, San Raffaele Foundation Scientific Institute, Milan, Italy

Tiziano di Tomaso

Gloria Sovena

- Infectious Disease and Immunogenetics Section, Dept. Transfusion Medicine, Clinical Center for Human Immunology, NIH, Bethesda, MD, USA
  - Ena Wang

Francesco Marincola

- Lorenzo Pilla
- Giorgio Parmiani

Dept. Neurosurgery, San Raffaele Foundation Hospital, Milan, Italy

Alberto Franzin

Pietro Mortini

Unit of Neural Stem Cell Biology, Div. • **Regenerative Medicine Stem Cells and Gene** Therapy, San Raffaele Foundation Scientific Institute, Milan, Italy

- Stefania Mazzoleni
- Rossella Galli


Dept. Of Surgery, Immunology and Pathology, **University of Pittsburgh Cancer Institute,** Pittsburgh, PA, USA

Soldano Ferrone


### A HYPOTHETICAL MODEL OF THE RELATIONSHIP BETWEEN PRIMARY TUMOR-DERIVED TUMOR STEM CELLS AND GBM TUMOR CELL LINES

à	NBE-cultured GBM cells	Serum-cultured GBM cells		
Proliferation	Constant	Limited growth, reaches plateau, followed by exponential growth		
Clonogenicity Tumorigenicity	Clonogenic and tumorigenic regardless of passages	Not at early passages		
Differentiation potential	Induce to become glial and neuronal lineages	Do not respond to differentiation stimuli		
Telomerase activity	Positive	Negative initially, but became positive at late passages		
Tumor histology	Extensive migration/infiltration Phenocopy primary human GBMs	Fail to show infiltration similar to common glioma lines		
Global gene expression	Similar to primary human GBMs	Different from primary tumors similar to common glioma lines		
NSC-related genes	Nestin, Sox2, CD133, Musashi, Bm			
Genotype	Same as parental tumors regardless of passages	Additional genomic alterations not found in parental tumors		

А



LEE J. ET AL., CANCER CELL 2006



#### **TUMORS CONTAINING CANCER STEM CELLS**

Acute myeloid leukemia (AML) CD34+ C

**CD34<sup>+</sup> CD38<sup>-</sup>** (Bonnet D et al, 1997; Hope KJ et al, 2004)

Chronic myeloid leukemia (CML)

**BREAST CANCER** 

**COLON CANCER** 

**PANCREATIC CANCER** 

**MELANOMA** 

PROSTATE

**LIVER CANCER** 

**GLIOMA** 

BCR-ABL CD34<sup>+</sup> CD38<sup>-</sup> (Barret et al, 2003)

CD44<sup>+</sup> CD24<sup>-/low</sup> (AL-Hajj Met al, 2003)

AC133<sup>+</sup> / ESA<sup>+</sup> CD44<sup>+</sup> CD166<sup>+</sup> (Ricci - Vitiani et, 2007; O**O**̃Brien et al, 2007; Li C et al, 2007)

**CD44<sup>+</sup> CD24<sup>+</sup> ESA<sup>+</sup>** (Prince ME, et al, 2007)

**CD20**<sup>+</sup> (Fang D et al, 2005)

**CD44**<sup>+</sup> **21**<sup>+</sup> **CD133**<sup>+</sup> (Collins AT et al, 2005)

**CD90<sup>+</sup> CD44<sup>+</sup>** (Yang ZF et al, 2008)

AC133<sup>+</sup> and/ or EGFR<sup>+</sup> (Sinh SK et al, 2004; Galli R et al, 2004; Liu G et al 2006)


### Aims

**To characterize the immune profile of CSCs isolated from GBM patients;** 


□ to analyze the immunobiological functions of GBM CSCs compared to their autologous differentiated tumor cells (grown *in vitro* in the presence of FBS and, referred as FBS tumor cells);

11 to define whether CSCs can represent suitable targets for immune based therapeutic interventions for GBM patients.

# IFN- $\alpha$ modulation of the expression of antigen processing molecules by CSCs



MRFIT ratio between the mean fluorescence intensity of colls stained with the selected mAb and that of cells stained with isotype-matched control mouse immunoglobulins.



#### Pro-angiogenic factor release by both GBM CSCs and FBS tumor cells